Evidence map›Paper›PMID 29746813›Full record

Trial reportContraception2018

Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.

Lameck Chinula, Julie A E Nelson, Jeffrey Wiener, Jennifer H Tang, Stacey Hurst, Gerald Tegha, Albans Msika, Sascha Ellington, Mina C Hosseinipour, Ronald Mataya and 2 more

Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Contraception, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Lameck ChinulaUniversity of North Carolina at Chapel Hill, Department of Obstetrics & Gynecology, Chapel Hill, USA; UNC Project-Malawi, Lilongwe, Malawi; Malawi College of Medicine, Department of Obstetrics & Gynecology, Blantyre, Malawi. Electronic address: lchinula@unclilongwe.org.
Julie A E NelsonUniversity of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, USA.
Jeffrey WienerUS. Centers for Disease Control and Prevention, Division of Reproductive Health, USA.
Jennifer H TangUniversity of North Carolina at Chapel Hill, Department of Obstetrics & Gynecology, Chapel Hill, USA; UNC Project-Malawi, Lilongwe, Malawi; Malawi College of Medicine, Department of Obstetrics & Gynecology, Blantyre, Malawi.
Stacey HurstUS. Centers for Disease Control and Prevention, Division of Reproductive Health, USA.
Gerald TeghaUNC Project-Malawi, Lilongwe, Malawi.
Albans MsikaUNC Project-Malawi, Lilongwe, Malawi.
Sascha EllingtonUS. Centers for Disease Control and Prevention, Division of Reproductive Health, USA.
Mina C HosseinipourUNC Project-Malawi, Lilongwe, Malawi; University of North Carolina at Chapel Hill, Division of Infectious Diseases, Chapel Hill, USA.
Ronald MatayaMalawi College of Medicine, Department of Obstetrics & Gynecology, Blantyre, Malawi; Loma Linda School of Public Health, Loma Linda, USA.
Lisa B HaddadEmory University, of Obstetrics & Gynecology, Atlanta, GA, USA.
Athena P KourtisUS. Centers for Disease Control and Prevention, Division of Reproductive Health, USA.
Centers for Disease Control and Prevention · USUniversity of North Carolina at Chapel Hill · USUniversity of Malawi · MWEmory University · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Evaluation of the immunologic and genital tract changes among Malawian women K01TW009657 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TANG, JENNIFER · 2013 to 2016
$565k
ACL HHS U48DP001944FIC NIH HHS K01 TW009657NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410
6 · The paper itself

Abstract

objectivesTo assess the effect of the depot medroxyprogesterone acetate injectable (DMPA) and of the levonorgestrel (LNG) implant on genital HIV shedding among women receiving antiretroviral therapy (ART).

methodsWe randomized HIV-infected Malawian women to either DMPA or LNG implant from May 2014 to April 2015. HIV RNA was measured in cervicovaginal lavage (CVL) fluid and TearFlo Strips (TFS), and HIV DNA was measured in cells collected by CVL. We compared the frequency and magnitude of HIV genital shedding before and for 6 months after initiation of contraception and between arms among women receiving ART. We also compared genital HIV RNA levels obtained by sample type (TFS versus CVL).

resultsWe analyzed data for 68 HIV-infected women receiving ART: 33 randomized to DMPA and 35 randomized to the LNG implant. Overall, HIV RNA was more often detectable and the quantity was higher on TFS compared with CVL. HIV DNA was detected very rarely in CVL cell samples (4 of 360 samples). The frequency of genital shedding and the genital HIV quantity did not increase after contraceptive initiation with either DMPA or LNG implant among women receiving ART.

conclusionsHIV-infected women receiving ART initiating contraception with either DMPA or LNG implant did not have any increase in genital HIV shedding during the first 6 months of contraceptive use. These findings are consistent with growing evidence that progestin contraception is not associated with increased HIV transmission risk from such women to their male partners. Consistent with other studies, genital HIV RNA detection was higher in TFS than in CVL fluid. IMPLICATIONS: In this randomized trial, neither DMPA nor the LNG implant, two of the most commonly used hormonal contraceptives among African women with HIV, was associated with increased genital HIV shedding in HIV-infected women receiving ART. These findings are reassuring and add to the currently limited information available for the highly effective contraceptive, LNG implant.

Indexed as

AdultAnti-Retroviral AgentsContraceptive Agents, FemaleFemaleHIVHIV InfectionsHumansLevonorgestrelMedroxyprogesterone AcetateVaginal SmearsVirus SheddingAnti-Retroviral AgentsContraceptive Agents, FemaleLevonorgestrelMedroxyprogesterone AcetateDepot medroxyprogesterone acetate injectableGenital sheddingHIVLevonorgestrel implantProgestin contraception

Identifiers

PMID29746813
PMCPMC6143482
OpenAlexW2801974904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.